Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.95
MASI's Cash to Debt is ranked higher than
62% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.27 vs. MASI: 0.95 )
MASI' s 10-Year Cash to Debt Range
Min: 0.49   Max: No Debt
Current: 0.95

Equity to Asset 0.53
MASI's Equity to Asset is ranked higher than
60% of the 453 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MASI: 0.53 )
MASI' s 10-Year Equity to Asset Range
Min: -1.01   Max: 0.81
Current: 0.53

-1.01
0.81
F-Score: 6
Z-Score: 5.48
M-Score: -2.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.72
MASI's Operating margin (%) is ranked higher than
88% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 5.49 vs. MASI: 14.72 )
MASI' s 10-Year Operating margin (%) Range
Min: -13.85   Max: 137.71
Current: 14.72

-13.85
137.71
Net-margin (%) 10.68
MASI's Net-margin (%) is ranked higher than
87% of the 458 Companies
in the Global Medical Devices industry.

( Industry Median: 3.95 vs. MASI: 10.68 )
MASI' s 10-Year Net-margin (%) Range
Min: -14.75   Max: 81.05
Current: 10.68

-14.75
81.05
ROE (%) 18.98
MASI's ROE (%) is ranked higher than
93% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 5.07 vs. MASI: 18.98 )
MASI' s 10-Year ROE (%) Range
Min: 17.28   Max: 40.82
Current: 18.98

17.28
40.82
ROA (%) 12.86
MASI's ROA (%) is ranked higher than
95% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. MASI: 12.86 )
MASI' s 10-Year ROA (%) Range
Min: -19.03   Max: 140.05
Current: 12.86

-19.03
140.05
ROC (Joel Greenblatt) (%) 69.43
MASI's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 473 Companies
in the Global Medical Devices industry.

( Industry Median: 8.37 vs. MASI: 69.43 )
MASI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 51.15   Max: 1358.08
Current: 69.43

51.15
1358.08
Revenue Growth (%) 12.50
MASI's Revenue Growth (%) is ranked higher than
86% of the 339 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MASI: 12.50 )
MASI' s 10-Year Revenue Growth (%) Range
Min: -19.3   Max: 30.3
Current: 12.5

-19.3
30.3
EBITDA Growth (%) -5.10
MASI's EBITDA Growth (%) is ranked higher than
70% of the 306 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. MASI: -5.10 )
MASI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 259.6
Current: -5.1

0
259.6
EPS Growth (%) -5.50
MASI's EPS Growth (%) is ranked higher than
71% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. MASI: -5.50 )
MASI' s 10-Year EPS Growth (%) Range
Min: -33.8   Max: 45.9
Current: -5.5

-33.8
45.9
» MASI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MASI Guru Trades in Q4 2013

Paul Tudor Jones 7,400 sh (New)
Mario Gabelli 34,000 sh (New)
Pioneer Investments 324,995 sh (+13.42%)
Jim Simons Sold Out
Joel Greenblatt 86,888 sh (-8.1%)
Ron Baron 1,370,014 sh (-32.95%)
» More
Q1 2014

MASI Guru Trades in Q1 2014

Jeremy Grantham 83,400 sh (New)
Paul Tudor Jones 24,500 sh (+231.08%)
Mario Gabelli 90,000 sh (+164.71%)
Pioneer Investments 338,961 sh (+4.3%)
Ron Baron 1,366,477 sh (-0.26%)
Joel Greenblatt 38,676 sh (-55.49%)
» More
Q2 2014

MASI Guru Trades in Q2 2014

Jim Simons 262,235 sh (New)
Joel Greenblatt 73,956 sh (+91.22%)
Paul Tudor Jones 37,000 sh (+51.02%)
Mario Gabelli 122,000 sh (+35.56%)
Jeremy Grantham 88,800 sh (+6.47%)
Pioneer Investments Sold Out
Ron Baron 758,386 sh (-44.5%)
» More
Q3 2014

MASI Guru Trades in Q3 2014

Jim Simons 336,200 sh (+28.21%)
Paul Tudor Jones 41,800 sh (+12.97%)
Mario Gabelli 125,000 sh (+2.46%)
Jeremy Grantham 75,535 sh (-14.94%)
Joel Greenblatt 55,059 sh (-25.55%)
Ron Baron 16,760 sh (-97.79%)
» More
» Details

Insider Trades

Latest Guru Trades with MASI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ron Baron 2014-09-30 Reduce -97.79%0.07%$20.69 - $24.64 $ 26.1915%16760
Joel Greenblatt 2014-09-30 Reduce -25.55%0.01%$20.69 - $24.64 $ 26.1915%55059
Ron Baron 2014-06-30 Reduce -44.5%0.07%$22.03 - $27.9 $ 26.196%758386
Joel Greenblatt 2014-06-30 Add 91.22%0.01%$22.03 - $27.9 $ 26.196%73956
Mario Gabelli 2014-06-30 Add 35.56%$22.03 - $27.9 $ 26.196%122000
Joel Greenblatt 2014-03-31 Reduce -55.49%0.03%$25.37 - $31.88 $ 26.19-8%38676
Mario Gabelli 2014-03-31 Add 164.71%0.01%$25.37 - $31.88 $ 26.19-8%90000
Ron Baron 2013-12-31 Reduce -32.95%0.08%$25.62 - $29.61 $ 26.19-6%1370014
Mario Gabelli 2013-12-31 New Buy0.01%$25.62 - $29.61 $ 26.19-6%34000
Joel Greenblatt 2013-09-30 Reduce -30.91%0.04%$21.55 - $27.04 $ 26.196%94545
Meridian Funds 2013-06-30 Add 130.2%0.27%$19.04 - $22.5 $ 26.1924%609110
Joel Greenblatt 2013-06-30 Add 34.41%0.03%$19.04 - $22.5 $ 26.1924%136838
Meridian Funds 2013-03-31 New Buy0.19%$19.51 - $21.33 $ 26.1930%264600
Joel Greenblatt 2013-03-31 Add 64.59%0.04%$19.51 - $21.33 $ 26.1930%101804
Joel Greenblatt 2012-12-31 Add 30.93%0.02%$20.22 - $24.11 $ 26.1921%61854
Joel Greenblatt 2012-09-30 Reduce -50.15%0.08%$21 - $24.87 $ 26.1915%47242
John Burbank 2012-06-30 Sold Out 0.08%$18.35 - $23.98 $ 26.1926%0
Joel Greenblatt 2012-06-30 Add 36.65%0.04%$18.35 - $23.98 $ 26.1926%94762
John Burbank 2012-03-31 New Buy0.08%$18.46 - $23.49 $ 26.1930%100000
Joel Greenblatt 2012-03-31 Add 110.46%0.07%$18.46 - $23.49 $ 26.1930%69345
Joel Greenblatt 2011-12-31 Add 74.44%0.03%$17.84 - $22.87 $ 26.1927%32950
Joel Greenblatt 2011-09-30 New Buy0.07%$20.96 - $30.91 $ 26.193%18889
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 24.50
MASI's P/E(ttm) is ranked higher than
88% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 106.60 vs. MASI: 24.50 )
MASI' s 10-Year P/E(ttm) Range
Min: 16.96   Max: 91.05
Current: 24.5

16.96
91.05
P/B 4.80
MASI's P/B is ranked higher than
65% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.78 vs. MASI: 4.80 )
MASI' s 10-Year P/B Range
Min: 3.54   Max: 15.2
Current: 4.8

3.54
15.2
P/S 2.60
MASI's P/S is ranked higher than
74% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 3.40 vs. MASI: 2.60 )
MASI' s 10-Year P/S Range
Min: 1.77   Max: 9.79
Current: 2.6

1.77
9.79
PFCF 2603.00
MASI's PFCF is ranked higher than
78% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 2603.00 )
MASI' s 10-Year PFCF Range
Min: 2.34   Max: 2642
Current: 2603

2.34
2642
EV-to-EBIT 14.94
MASI's EV-to-EBIT is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 73.45 vs. MASI: 14.94 )
MASI' s 10-Year EV-to-EBIT Range
Min: 6.3   Max: 117.2
Current: 14.94

6.3
117.2
PEG 123.00
MASI's PEG is ranked higher than
86% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 123.00 )
MASI' s 10-Year PEG Range
Min: 0.38   Max: 256.67
Current: 123

0.38
256.67
Shiller P/E 24.20
MASI's Shiller P/E is ranked higher than
93% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 24.20 )
MASI' s 10-Year Shiller P/E Range
Min: 14.15   Max: 30.84
Current: 24.2

14.15
30.84
Current Ratio 1.25
MASI's Current Ratio is ranked higher than
50% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 2.72 vs. MASI: 1.25 )
MASI' s 10-Year Current Ratio Range
Min: 1.25   Max: 4.87
Current: 1.25

1.25
4.87
Quick Ratio 0.99
MASI's Quick Ratio is ranked higher than
52% of the 474 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. MASI: 0.99 )
MASI' s 10-Year Quick Ratio Range
Min: 0.99   Max: 4.34
Current: 0.99

0.99
4.34

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.90
MASI's Price/Tangible Book is ranked higher than
71% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 6.57 vs. MASI: 5.90 )
MASI' s 10-Year Price/Tangible Book Range
Min: 4.11   Max: 15.3
Current: 5.9

4.11
15.3
Price/DCF (Projected) 1.70
MASI's Price/DCF (Projected) is ranked higher than
91% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 1.70 )
MASI' s 10-Year Price/DCF (Projected) Range
Min: 1.22   Max: 2.52
Current: 1.7

1.22
2.52
Price/Median PS Value 0.80
MASI's Price/Median PS Value is ranked higher than
89% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 1.21 vs. MASI: 0.80 )
MASI' s 10-Year Price/Median PS Value Range
Min: 0.63   Max: 2.74
Current: 0.8

0.63
2.74
Price/Graham Number 2.40
MASI's Price/Graham Number is ranked higher than
85% of the 511 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MASI: 2.40 )
MASI' s 10-Year Price/Graham Number Range
Min: 1.76   Max: 5.96
Current: 2.4

1.76
5.96
Earnings Yield (Greenblatt) 6.70
MASI's Earnings Yield (Greenblatt) is ranked higher than
91% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MASI: 6.70 )
MASI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.9   Max: 15.8
Current: 6.7

0.9
15.8
Forward Rate of Return (Yacktman) 2.32
MASI's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 349 Companies
in the Global Medical Devices industry.

( Industry Median: 0.59 vs. MASI: 2.32 )
MASI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.9   Max: 64.3
Current: 2.32

2.9
64.3

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:3M4.Germany
Masimo Corp was incorporated in California in May 1989 and reincorporated in Delaware in May 1996. The Company is a medical technology company that develops, manufactures, and markets a variety of noninvasive monitoring technologies. Its core business is measure through motion and low perfusion arterial blood oxygen saturation and pulse rate monitoring, known as Masimo SET pulse oximetry, but our product offerings have expanded significantly over the years to also include noninvasive blood constituent, brain and breath monitoring, including rainbow Pulse CO-Oximetry, brain function electroencephalogram (EEG) monitoring, respiration rate, capnography and anesthetic agent monitoring. In addition, they have developed the Root patient monitoring and connectivity platform and Patient SafetyNet remote patient surveillance monitoring system. They provide their products directly and through distributors and OEM partners to hospitals, emergency medical service (EMS) providers, physician offices, veterinarians, long term care facilities and consumers. The Company sell their products to end-users through its direct sales force and certain distributors, as well as its OEM partners, for incorporation into their products. They also offer a patient surveillance or remote monitoring and clinician notification solution called Patient SafetyNet, which includes Masimo SET or rainbow SET platform measurements at the patient's bedside along with a central assignment station and wired or wireless server. In October 2012, they received both FDA clearance for uSpO2, a universal "Board-in-Cable" pulse oximetry solution, enabling easier and faster integration for OEM partners due to the ability to integrate Masimo SET through software only. The Company acquired Spire Semiconductor, LLC, a maker of advanced light emitting diode and other advanced component-level technologies. Masimo Semiconductor, Inc. (Masimo Semiconductor), its wholly owned subsidiary, operates this business and specializes in wafer epitaxy, foundry services, and device fabrication for biomedical, telecommunications, consumer products and other markets. The Company offer Masimo SET and rainbow SET through its OEMs for integration in their products and through its own end-user products, including the Root, Radical-7, Rad-87, Rad-57, Pronto-7, Pronto, Rad-8, Rad-5 and Rad-5v. The Company has 674 issued and pending patents worldwide. They have licensed from Cercacor Laboratories, Inc. (Cercacor), the right to OEM selected rainbow technology and to incorporate selected rainbow technology into their products intended to be used by professional caregivers, including, but not limited to, hospital caregivers and alternate care facility caregivers. The Company is subject to U.S. Food, Drug, and Cosmetic Act (FDCA) and the regulations promulgated under that Act, the FDA regulates the design, development, clinical trials, testing, manufacture, packaging, labeling, storage, distribution and promotio
» More Articles for MASI

Headlines

Articles On GuruFocus.com
New Clinical Study Shows Accuracy of Masimo Noninvasive Spot-Check Hemoglobin (SpHb(R)) in Trauma Pa Nov 05 2014 
Arkansas Heart Hospital Upgrades to Masimo SET(R) Pulse Oximetry, Resulting in Significant Reduction Oct 23 2014 
Masimo to Report Third Quarter 2014 Financial Results After Market Close on Wednesday, October 29th Oct 17 2014 
Two New Clinical Studies Show Masimo Noninvasive Hemoglobin (SpHb(R)) Demonstrated Similar Precision Oct 16 2014 
New Clinical Study Presented at the American Society of Anesthesiologists Annual Meeting Shows Benef Oct 15 2014 
Masimo Announces CE Mark of the 11th Rainbow(R) Parameter - ORI(TM), Oxygen Reserve Index(TM) Oct 15 2014 
Newborn Foundation Bestows Masimo CEO Joe Kiani With the Hubert H. Humphrey 'Dawn of Life' Award Oct 15 2014 
Mercy Hospital of Buffalo Expands Use of Masimo Patient SafetyNet(TM) After Pilot Program Shows Redu Oct 15 2014 
Masimo Announces CE Mark of Eve(TM) Newborn Screening Application for Radical-7, an Intuitive Softwa Oct 15 2014 
Retrospective Study of Enhanced Recovery After Surgery Program for Patients Undergoing Colorectal Su Oct 15 2014 

More From Other Websites
Masimo to Present at 26th Annual Piper Jaffray Health Care Conference Nov 18 2014
Masimo to Present at 26th Annual Piper Jaffray Health Care Conference Nov 18 2014
MASIMO CORP Financials Nov 05 2014
New Clinical Study Shows Accuracy of Masimo Noninvasive Spot-Check Hemoglobin (SpHb(R)) in Trauma... Nov 05 2014
New Clinical Study Shows Accuracy of Masimo Noninvasive Spot-Check Hemoglobin (SpHb(R)) in Trauma... Nov 05 2014
10-Q for Masimo Corp. Oct 31 2014
Masimo Beats Q3 Earnings Estimates, Cuts Revenue Outlook Oct 30 2014
Masimo beats 3Q profit forecasts Oct 30 2014
Masimo beats 3Q profit forecasts Oct 30 2014
Masimo Corp Earnings Call scheduled for 4:30 pm ET today Oct 29 2014
MASIMO CORP Files SEC form 8-K, Results of Operations and Financial Condition Oct 29 2014
Masimo Reports Third Quarter 2014 Financial Results Oct 29 2014
Q3 2014 Masimo Corp Earnings Release - After Market Close Oct 29 2014
Arkansas Heart Hospital Upgrades to Masimo SET(R) Pulse Oximetry, Resulting in Significant Reduction... Oct 23 2014
Arkansas Heart Hospital Upgrades to Masimo SET(R) Pulse Oximetry, Resulting in Significant Reduction... Oct 23 2014
Masimo to Report Third Quarter 2014 Financial Results After Market Close on Wednesday, October 29th Oct 17 2014
Masimo to Report Third Quarter 2014 Financial Results After Market Close on Wednesday, October 29th Oct 17 2014
Les nouvelles études cliniques démontrent que le dispositif de contrôle non-invasif de... Oct 16 2014
Two New Clinical Studies Show Masimo Noninvasive Hemoglobin (SpHb(R)) Demonstrated Similar Precision... Oct 16 2014
Two New Clinical Studies Show Masimo Noninvasive Hemoglobin (SpHb(R)) Demonstrated Similar Precision... Oct 16 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK